PH26712A - Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt - Google Patents

Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt Download PDF

Info

Publication number: PH26712A
Authority: PH; Philippines
Prior art keywords: weight; composition; optionally; cholinergic; salt
Prior art date: 1987-07-30

Application number

PH37251A

Other languages

English (en)

Inventor

Franklin Muny Boghen

Franco Camanni

Ezio Ghigo

Piero Del Soldato

Eugenio Muller

Original Assignee

Franklin Muny Boghen

Franco Camanni

Ezio Ghigo

Piero Del Soldato

Eugenio Muller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-30

Filing date

1988-07-21

Publication date

1992-09-15

1988-07-21 Application filed by Franklin Muny Boghen, Franco Camanni, Ezio Ghigo, Piero Del Soldato, Eugenio Muller filed Critical Franklin Muny Boghen

1992-09-15 Publication of PH26712A publication Critical patent/PH26712A/en

Links

239000003833 bile salt Substances 0.000 title description 6
239000000064 cholinergic agonist Substances 0.000 title description 2
239000008194 pharmaceutical composition Substances 0.000 title 1
239000003488 releasing hormone Substances 0.000 title 1
239000000203 mixture Substances 0.000 claims description 26
102100022831 Somatoliberin Human genes 0.000 claims description 16
101710142969 Somatoliberin Proteins 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
230000001713 cholinergic effect Effects 0.000 claims description 9
229960002362 neostigmine Drugs 0.000 claims description 7
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims description 7
210000000941 bile Anatomy 0.000 claims description 6
208000037824 growth disorder Diseases 0.000 claims description 5
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
239000000556 agonist Substances 0.000 claims description 3
159000000011 group IA salts Chemical class 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims 4
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
241000270276 Natrix Species 0.000 claims 1
RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 claims 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
239000000839 emulsion Substances 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical group C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims 1
229960002329 methacholine Drugs 0.000 claims 1
229940100652 nasal gel Drugs 0.000 claims 1
229940100657 nasal ointment Drugs 0.000 claims 1
229960001697 physostigmine Drugs 0.000 claims 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
230000002459 sustained effect Effects 0.000 claims 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
229960001661 ursodiol Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 21
239000012153 distilled water Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 3
235000015107 ale Nutrition 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
244000248349 Citrus limon Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
-1 cresm Substances 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960003748 edrophonium Drugs 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
239000010520 ghee Substances 0.000 description 1
WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960002931 methacholine chloride Drugs 0.000 description 1
JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003248 quinolines Chemical group 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000000542 thalamic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Otolaryngology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PH37251A 1987-07-30 1988-07-21 Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt PH26712A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT21513/87A IT1222395B (it)	1987-07-30	1987-07-30	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare

Publications (1)

Publication Number	Publication Date
PH26712A true PH26712A (en)	1992-09-15

Family

ID=11182925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH37251A PH26712A (en)	1987-07-30	1988-07-21	Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt

Country Status (12)

Country	Link
US (1)	US5010056A (de)
EP (1)	EP0301392B1 (de)
JP (1)	JPS6450823A (de)
KR (1)	KR890001584A (de)
AT (1)	ATE76753T1 (de)
AU (1)	AU618547B2 (de)
DK (1)	DK393188A (de)
IT (1)	IT1222395B (de)
NO (1)	NO883200L (de)
NZ (1)	NZ225546A (de)
PH (1)	PH26712A (de)
ZA (1)	ZA885417B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0383931A (ja) *	1989-08-29	1991-04-09	Sumitomo Pharmaceut Co Ltd	低刺激性ｇｒｆ経鼻投与製剤
DE69001991T2 (de) *	1989-11-16	1993-09-23	Phidea Spa	Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.
US5502067A (en) *	1994-02-04	1996-03-26	Morgan; Julia A.	Treating apneahypopnea/snoring in humans
US5500205A (en) *	1994-02-23	1996-03-19	Enviro Pac International, L.I.C.	Lachrymator aerosol formulations
US5861431A (en) *	1995-06-07	1999-01-19	Iotek, Inc.	Incontinence treatment
AUPN801296A0 (en) *	1996-02-12	1996-03-07	Csl Limited	Stabilised growth hormone formulation and method of preparation thereof
US8048875B1 (en)	1997-02-24	2011-11-01	S.L.A. Pharma Ag	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
CA2281755C (en) *	1997-02-24	2006-11-07	Michael Albert Kamm	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
ATE289825T1 (de) *	1999-04-21	2005-03-15	1355540 Ontario Inc	Methacoline oder histamine formulierungen zur feststellung von asthma
EP1189596A1 (de) *	1999-06-02	2002-03-27	Norbert Dr.med. Klöcker	Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen
AU1261501A (en) *	1999-12-06	2001-06-18	Stanley L. Gore	Compositions and methods for intranasal delivery of active agents to the brain
JP3498041B2 (ja)	2000-05-29	2004-02-16	科研製薬株式会社	プラルモレリン含有点鼻用製剤
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) *	2009-05-22	2010-11-25	Kaufman Herbert E	Preparations and Methods for Ameliorating or Reducing Presbyopia
BR112016002268B1 (pt) *	2013-08-01	2022-11-01	The Penn State Research Foundation	Uso de inibidores do receptor x farnesoide
CA3190833A1 (en) *	2020-08-26	2022-03-03	Michael Mcdonald CROWLEY	Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3371281D1 (en) *	1982-12-10	1987-06-11	Syntex Inc	Lhrh preparations for intranasal administration
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
IT1169873B (it) *	1983-10-21	1987-06-03	Prodotti Formenti Srl	Composizione farmaceutica ad attivita' sistemica anticolinesterasica, agonista-colinergica ed antimuscarinica
US4818531A (en) *	1985-02-06	1989-04-04	Eli Lilly And Company	Growth hormone and thyroid hormone
JPS62126135A (ja) *	1985-11-25	1987-06-08	Sumitomo Pharmaceut Co Ltd	経鼻投与用ｇｒｆ製剤
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
US4880778A (en) *	1986-05-12	1989-11-14	Eastman Kodak Company	Combinations having synergistic growth hormone releasing activity and methods for use thereof

1987
- 1987-07-30 IT IT21513/87A patent/IT1222395B/it active
1988
- 1988-07-14 DK DK393188A patent/DK393188A/da not_active Application Discontinuation
- 1988-07-19 NO NO88883200A patent/NO883200L/no unknown
- 1988-07-20 AT AT88111657T patent/ATE76753T1/de active
- 1988-07-20 EP EP88111657A patent/EP0301392B1/en not_active Expired - Lifetime
- 1988-07-21 PH PH37251A patent/PH26712A/en unknown
- 1988-07-25 ZA ZA885417A patent/ZA885417B/xx unknown
- 1988-07-25 US US07/223,378 patent/US5010056A/en not_active Expired - Fee Related
- 1988-07-25 NZ NZ225546A patent/NZ225546A/en unknown
- 1988-07-26 AU AU20051/88A patent/AU618547B2/en not_active Ceased
- 1988-07-27 KR KR1019880009436A patent/KR890001584A/ko not_active Withdrawn
- 1988-07-28 JP JP63187052A patent/JPS6450823A/ja active Pending

Also Published As

Publication number	Publication date
IT1222395B (it)	1990-09-05
NO883200L (no)	1989-01-31
NZ225546A (en)	1990-12-21
AU618547B2 (en)	1992-01-02
AU2005188A (en)	1989-02-02
US5010056A (en)	1991-04-23
EP0301392A1 (de)	1989-02-01
ZA885417B (en)	1989-06-28
ATE76753T1 (de)	1992-06-15
DK393188A (da)	1989-01-31
IT8721513A0 (it)	1987-07-30
EP0301392B1 (en)	1992-06-03
KR890001584A (ko)	1989-03-27
NO883200D0 (no)	1988-07-19
DK393188D0 (da)	1988-07-14
JPS6450823A (en)	1989-02-27

Publication	Publication Date	Title
CA1288048C (en)	1991-08-27	Aqueous steroid formulations for nasal administration
EP0498069B1 (de)	1995-10-25	Neue Verwendung von Peptidderivat
KR101546596B1 (ko)	2015-08-21	베포타스틴 조성물
US8859531B2 (en)	2014-10-14	Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
AU2010287421B2 (en)	2013-06-13	Therapeutic agent for rhinitis
HU227519B1 (en)	2011-07-28	Synergic pharmaceutical composition containing combination of formoterol and budesonide
US4983595A (en)	1991-01-08	Aqueous steroid formulations for nasal administration
BG106946A (bg)	2003-05-30	Използване на антагонисти на централни канабиноидни рецептори за получаване на лекарствени средстваза улесняване спирането на консумацията на тютюн
CA2277365A1 (en)	1998-07-16	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6521266B1 (en)	2003-02-18	Composition for growth hormone production and release, appetite suppression, and methods related thereto
JP2003505419A (ja)	2003-02-12	ケトチフェンを含む眼用組成物
US5010056A (en)	1991-04-23	Pharmaceutical composition for intranasal administration, comprising GH-releasing hormone, a cholinergic agonist and optionally a bile salt
Derelanko et al.	1981	Carbenoxolone sodium protects rat gastric mucosa against ethanol-induced necrosis
EP0843998B1 (de)	2002-02-13	Orale pharmazeutische Zubereitung mit antipyretischer, analgetischer und entzündungshemmender Wirkung.
CA1223210A (en)	1987-06-23	Antisnoring agent
AU637773B2 (en)	1993-06-10	Fruity flavoured nasal decongestant composition
IL148691A (en)	2006-12-10	Pharmaceutical preparations containing cyclosonide
US20020114832A1 (en)	2002-08-22	Pharmaceutical preparation comprising peppermint oil and caraway oil in delayed release form
EP1782816A1 (de)	2007-05-09	Medizinische zusammensetzung auf wasserbasis mit azithromycin und herstellungsverfahren dafür
HU194736B (en)	1988-03-28	Improved process for production of antiinflammable preparative
JP2891738B2 (ja)	1999-05-17	アルコール吸収抑制剤
JP3665616B2 (ja)	2005-06-29	ローヤルゼリー製剤
JP2885668B2 (ja)	1999-04-26	テプレノン製剤
ZA200500064B (en)	2005-11-02	Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
JP2004075571A (ja)	2004-03-11	点鼻剤およびその製造方法